Medical Need for New & Effective Antifungal
PAC-113, an anti-fungal for the treatment of oral Candidiasis infections, completed a Phase IIb clinical program in mid 2008.
Opportunistic growth of Candida occurs in people with defective immune systems, or as a result of salivary dysfunction, and can be life-threatening if not treated. Candida albicans is the most common fungal pathogen among immune-compromised, hospitalized patients, accounting for roughly 50-60% of all bloodstream fungal isolates. Localized Candida infections, if untreated, can spread from the primary site of infection through the blood stream to cause a disseminated infection. Disseminated fungal infections are associated with a high mortality rate.